$PPHM Company News

New Post Public Reply Private Reply Replies (0) Message Board

Sep 24, 2014 at 12:31 PM

$PPHM Company News

Apollo slammed on education department review
6:09 p.m. July 14, 2014
- Tom Bemis

Peregrine plunges on test data

4:17 p.m. June 27, 2013
- Russ Britt

Small-cap makes a splash with FDA nod for cancer drug

3:16 p.m. May 20, 2013
- Russ Britt

Peregrine drug shows promise in pancreatic cancer
1:17 p.m. Feb. 13, 2013
- MarketWatch.com

In focus: Bullish, but overbought
8:06 p.m. Jan. 9, 2013
- Lawrence G. McMillan

Hedge funds are bullish on these stocks
11:57 a.m. Dec. 5, 2012
- Insider Monkey

Peregrine, FDA agree on brain-cancer drug study
11:56 a.m. Dec. 5, 2012
- MarketWatch.com

Drug trial contractors improve efficiency
10:24 a.m. Nov. 16, 2012
- MarketWatch.com

Monday’s biggest gaining and declining stocks
6:42 p.m. Sept. 25, 2012
- Greg Morcroft

Tuesday’s biggest gaining and declining stocks
5:09 p.m. Sept. 25, 2012
- Greg Morcroft

Peregrine Pharma down 86% after test data review
8:27 a.m. Sept. 24, 2012
- Steve Gelsi

Peregrine Pharma down 86% in premarket
8:18 a.m. Sept. 24, 2012
- Steve Gelsi

Peregrine reviewing Bavituximab results
7:42 a.m. Sept. 24, 2012
- Greg Morcroft

Some previous Bavituximab data not valid

eregrine
7:42 a.m. Sept. 24, 2012
- Greg Morcroft

Monday’s biggest gaining and declining stocks
2:42 p.m. Sept. 10, 2012
- MarketWatch

Regions Financial, Williams-Sonoma hit 52-week highs; Intel, Cisco active

11:11 a.m. Sept. 10, 2012
- blogs.marketwatch.com

Stocks to watch Monday: AIG, Michael Kors, Sears
6:41 a.m. Sept. 10, 2012
- MarketWatch

Peregrine rallies on bavituximab lung-cancer data
1:29 p.m. Sept. 7, 2012
- MarketWatch.com

Monday’s biggest gaining & declining stocks
2:53 p.m. Aug. 27, 2012
- MarketWatch

Peregrine Pharma slides 12% after negative report
2:21 p.m. Aug. 27, 2012
- Val Brickates Kennedy

Peregrine Pharmaceuticals' Q1 Loss Wider than Expected - Analyst Blog

9:00 a.m. Sept. 10, 2014
- Zacks.com

Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q1 2015 Results - Earnings Call Transcript

7:53 p.m. Sept. 9, 2014
- Seeking Alpha

10-Q: PEREGRINE PHARMACEUTICALS INC
4:29 p.m. Sept. 9, 2014
- Edgar Online - (EDG = 10Q, 10K)

Peregrine Pharmaceuticals (PPHM) Q1 2015 Results - Earnings Call Webcast

4:25 p.m. Sept. 9, 2014
- Seeking Alpha

Tekmira Pharmaceuticals Corp. Is More Than Just A Short-Term Trade

3:12 p.m. Aug. 27, 2014
- Seeking Alpha

Cel-Sci Is A Leader In The I-O Class Of Cancer Therapies

10:43 a.m. Aug. 12, 2014
- Seeking Alpha

Peregrine Pharmaceuticals' Q4 Loss Narrower than Expected - Analyst Blog

11:00 a.m. July 15, 2014
- Zacks.com

Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q4 2014 Results - Earnings Call Transcript

10:21 p.m. July 14, 2014
- Seeking Alpha

10-K: PEREGRINE PHARMACEUTICALS INC
5:00 p.m. July 14, 2014
- Edgar Online - (EDG = 10Q, 10K)

More on Peregrine fiscal Q4 and fiscal year results

4:26 p.m. July 14, 2014
- Seeking Alpha

Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events

9:30 a.m. July 14, 2014
- TheStreet.com

First Week Of January 2015 Options Trading For Peregrine Pharmaceuticals (PPHM)

11:09 a.m. May 20, 2014
- TheStreet.com

Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack

6:00 a.m. May 9, 2014
- TheStreet.com

Peregrine wins law suit

9:24 a.m. May 5, 2014
- Seeking Alpha

Medivation Signs Deal with OncoFusion Therapeutics - Analyst Blog

6:24 p.m. April 24, 2014
- Zacks.com

Interesting PPHM Call Options For June 21st

11:02 a.m. April 23, 2014
- TheStreet.com

Peregrine's Bavituximab has high success rate in animal testing

9:47 a.m. April 7, 2014
- Seeking Alpha

Peregrine Pharmaceuticals (PPHM) Shares March Higher, Can It Continue? - Tale of the Tape

8:39 a.m. March 18, 2014
- Zacks.com

Cel-Sci's Multikine - Potential 21st Century Superdrug

5:41 p.m. March 13, 2014
- Seeking Alpha

Peregrine antibodies boost anti-tumor activity in animal studies

9:47 a.m. March 11, 2014
- Seeking Alpha

Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2015
Financial Results and Recent Developments
4:01 p.m. Sept. 9, 2014
- Marketwire

Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E
Convertible Preferred Stock
4:00 p.m. Sept. 8, 2014
- Marketwire

Peregrine Pharmaceuticals to Report First Quarter Fiscal Year 2015
Financial Results After Market Close on September 9, 2014
4:01 p.m. Sept. 2, 2014
- Marketwire

Preclinical Data Presented at Annual Immunotherapies and Vaccine
Summit Show That the Combination of Peregrine Pharmaceuticals'
PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce
Breast Cancer Progression
8:03 a.m. Aug. 11, 2014
- Marketwire

Small companies lead the I-O class of Cancer Therapies
8:03 a.m. Aug. 8, 2014
- ACCESSWIRE

Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma
9:00 a.m. Aug. 1, 2014
- PR Newswire - PRF

Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal
Year 2014 Financial Results and Recent Developments
4:01 p.m. July 14, 2014
- Marketwire

Peregrine Pharmaceuticals to Report Fourth Quarter and Year-End
Fiscal 2014 Financial Results After Market on July 14, 2014
4:00 p.m. July 7, 2014
- Marketwire

Technical Scrutiny on Biotech Stocks -- Research on Insmed, Peregrine Pharma, CytRx, and Celldex Therapeutics
6:40 a.m. June 30, 2014
- PR Newswire - PRF

Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E
Convertible Preferred Stock
4:00 p.m. June 10, 2014
- Marketwire

Pre-Market Review on Biotechnology Equities -- Research on BioMarin Pharma, Keryx Biopharma, Amgen, and Peregrine Pharma
8:30 a.m. May 30, 2014
- PR Newswire - PRF

Biotech Stocks Scanner -- Research on PDL BioPharma, Cytokinetics, Vical, and Peregrine Pharma
12:41 p.m. May 6, 2014
- PR Newswire - PRF

Peregrine Pharmaceuticals Announces Initiation of an
Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab
and Ipilimumab (Yervoy(R)) in Advanced Melanoma
7:31 a.m. April 23, 2014
- Marketwire

Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Therapeutics, Peregrine Pharmaceuticals, and VIVUS
12:28 p.m. April 10, 2014
- PR Newswire - PRF

Data Presented at AACR Support Potential of Peregrine's PS-Targeting
Immunotherapy Bavituximab to Enhance Anti-Tumor and
Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in
Models of Melanoma and Colon Cancer
11:01 a.m. April 9, 2014
- Marketwire

Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma
1:15 p.m. April 8, 2014
- PR Newswire - PRF

Data Presented at AACR Support Potential of Combining Peregrine's
PS-Targeting Immunotherapy Agent Bavituximab With Irradiation in Lung
Cancer
8:04 a.m. April 7, 2014
- Marketwire

Peregrine Pharmaceuticals Announces Three Abstracts Accepted for
Presentation at AACR 2014 Annual Meeting
4:01 p.m. April 1, 2014
- Marketwire

Presentation at Annual Society of Surgical Oncology Meeting Updates
Progress in Investigator-Sponsored Phase i/ii Trial of Peregrine's
Bavituximab in Combination With Sorafenib in Liver Cancer
8:02 a.m. March 14, 2014
- Marketwire

Preclinical Data Presentations at Keystone Symposia Highlight Broad
Immunotherapy Potential of Peregrine Pharmaceuticals' PS-Targeting
Antibodies
8:02 a.m. March 13, 2014
- Marketwire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Modeling and Mental Health Join Forces for Wellness

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

XKL Delivers MediaLight for High-Speed Optical Transport

Unpacking the MediaLight Launch Kicking off September, XKL is tossing its hat in the ring with the MediaLight Xponder and Muxponder systems. These aren't just any run-of-the-mill gizmos—nope, they're touted as top-of-the-line optical transport solutions. The talk of the town is their ability to dish out high-density 100G and 400G transport, and for geeks in the trade,...

Intus Bio Secures $2.7M for Colorectal Cancer Test

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

SES Sells to AFC Industries: A Strategic M&A Move

Nashville's Notable Deal in Industrial Supply On a muggy September day in Nashville, XLCS Partners announced it was at the helm of a noteworthy transaction—the sale of Signature Engineered Solutions (SES) to AFC Industries. Now, this isn't just another corporate shuffle; it's a calculated move in the gritty world of fastening and engineered solutions. The Nitty-Gritty...

DCM Services Teams with AKUVO to Boost Estate Recoveries

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

BusyBee AI Revolutionizes Classroom Feedback Efficiency

Grading Overhaul: BusyBee's Role in Education Here's a twist for the history books: Agilix Labs' BusyBee, a slick AI assistant built right into the Buzz platform on Amazon Bedrock, is kicking traditional grading methods to the curb. This little helper is grading close to a million K-12 student submissions every month, meticulously approved by real teachers. Quite the...

Seismic Pharma Kicks Off Phase 3 Trial for Istaroxime

Seismic Sets the Stage for a Medical Milestone From the heart of biotech in Durham, North Carolina, seismic waves ripple through the medical community as Seismic Pharmaceuticals embarks on a high-stakes adventure. It's official: they've enrolled their very first patient in the global Phase 3 trial of istaroxime, targeting the grim specter known as cardiogenic shock. You...

Moore Law Investigates Aardvark Therapeutics' Risks

Moore Law Launches Probe Into Aardvark Therapeutics Nobody likes stumbling across bad news over their morning coffee, but sometimes the market loves to keep you on your toes. Now it's Aardvark Therapeutics (NASDAQ: AARD) in the headlines, and not how they'd like. This time, Moore Law PLLC is rolling up its sleeves to dig into potential misconduct by the company's top...

Step Inside Henson's Creature Shop Magic in NYC

Unlock Puppet Magic with Jim Henson Tours Puppet fans, let me tell you, there's something going on in Queens, NY that's got both nostalgia and innovation scribbled all over it. We're talking about the legendary Jim Henson's Creature Shop opening its doors. If you're looking to relive the magic that helped shape a generation, get ready to dive into a world where creativity...

QuickFi Nabs Top Finovate Award for Fourth Time

An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...